Inventor
BORRAS LEONARDO
CH21 patents
⚠️ This page may combine multiple inventors who share the name “BORRAS LEONARDO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ESBATECH ALCON BIOMED RES UNIT
7 patentsUS9090684B2Jul 28, 2015
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT54 citations97
US9422366B2Aug 23, 2016
Stable and soluble antibodies inhibiting TNF alpha
ESBATECH ALCON BIOMED RES UNIT12 citations92
US8349322B2Jan 8, 2013
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT31 citations92
US10590193B2Mar 17, 2020
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT9 citations83
US10100111B2Oct 16, 2018
Stable and soluble antibodies inhibiting TNF alpha
ESBATECH ALCON BIOMED RES UNIT7 citations83
US9873737B2Jan 23, 2018
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT10 citations83
US10221237B2Mar 5, 2019
Solubility optimization of immunobinders
ESBATECH ALCON BIOMED RES UNIT0 citations52
BORRAS LEONARDO
4 patentsUS8673310B2Mar 18, 2014
Stable and soluble antibodies inhibiting TNFα
BORRAS LEONARDO36 citations97
US8293235B2Oct 23, 2012
Humanization of rabbit antibodies using a universal antibody framework
BORRAS LEONARDO49 citations97
US8937162B2Jan 20, 2015
Humanization of rabbit antibodies using a universal antibody framework
BORRAS LEONARDO14 citations92
US9556265B2Jan 31, 2017
Solubility optimization of immunobinders
BORRAS LEONARDO3 citations72
NOVARTIS AG
4 patentsUS11858981B2Jan 2, 2024
Humanization of rabbit antibodies using a universal antibody framework
NOVARTIS AG0 citations62
US11578123B2Feb 14, 2023
Stable and soluble antibodies inhibiting TNFα
NOVARTIS AG0 citations62
US11046757B2Jun 29, 2021
Solubility optimization of immunobinders
NOVARTIS AG0 citations62
US10781268B2Sep 22, 2020
Method for decreasing immunogenicity
NOVARTIS AG0 citations52
CDR LIFE AG
3 patentsUS11912771B2Feb 27, 2024
MAGE-A4 peptide-MHC antigen binding proteins
CDR LIFE AG2 citations62
US12344663B2Jul 1, 2025
Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CDR LIFE AG0 citations48
US12161673B2Dec 10, 2024
MAGE-A4 peptide dual T cell engagers
CDR LIFE AG0 citations38